Methods for detecting sinusoidal obstructive syndrome (SOS)
AssigneeIndiana Research & Technology Corporation
InventorSophie Paczesny
Life of this patent
Estimating the term…
Abstract
Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
Claims6
A method of detecting the presence of proteins L-Ficolin, hyaluronic acid (HA), and IL-1RL1 (ST2) that constitute a biomarker panel, in a subject receiving hematopoietic cell transplantation (HCT), the method comprising:
- providing a biological sample from the subject;
- contacting the biological sample obtained from the subject with (i) a first agent that specifically binds to L-Ficolin and forms a first agent-biomarker complex;
- (ii) a second agent that specifically binds to HA and forms a second agent-biomarker complex;
- and (iii) a third agent that specifically binds to IL-1RL1 (ST2) and forms a third agent-biomarker complex;
- and
- detecting the formation of each first, second and third agent-biomarker complexes, thereby determining the presence of the biomarker panel in said biological sample.
A method of treating sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), said the method comprising
- identifying a patient at risk SOS by
- obtaining a biological sample from a subject receiving HSCT;
- measuring in said biological sample from the subject the expression of at least three biomarkers selected from the group consisting of L-Ficolin, hyaluronic acid (HA) IL-1RL1 (ST2), and VCAM1 by contacting the biological sample obtained from the subject with specific binding agents that specifically bind to each of the respective the biomarkers, wherein the each specific binding agent forms a complex with the respective biomarker;
- and
- detecting the agent-biomarker complexes, thereby determining the biomarker expression level;
- wherein an elevated biomarker expression level of said at least three biomarkers compared to biomarker expression obtained from a biological sample obtained from a control is indicative of SOS;
- and
- treating said patient at risk of SOS with defibrotide.
A method of treating sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), said method comprising:
- administering defibrotide to a subject identified as being in need of treatment, wherein said subject identified as being in need of treatment for SOS has an elevated biomarker expression level of at least three biomarkers selected from the group consisting of L-Ficolin, hyaluronic acid (HA), IL-1RL1 (ST2), and VCAM1, relative to the corresponding biomarker expression obtained from a control.
Dependencies are inferred from the claim text.